HIMS Stock Dives Sharply as Uninsured Patients Raise Concerns while FDA Process Remains Uncertain

Quick overview

Hims & Hers stock plunged 13% to $28.50 after briefly rallying above $35, as concerns over uninsured patients and healthcare industry margins overshadowed a potential $440 million peptide opportunity.

Hims & Hers Stock Plunges 13% as Insurance Concerns Overshadow Peptide Opportunity

Hims & Hers Health stock suffered a sharp reversal, falling around 13% to approximately $28.50 after gaining 3.4% to $32.74 in the previous session. The decline came as broader healthcare concerns emerged, overshadowing optimism surrounding potential regulatory developments for compounded peptides.

Uninsured Patient Concerns Weigh on Healthcare Stocks

The latest HIMS decline also comes amid broader concerns about the healthcare industry’s payer environment.

HCA Healthcare recently highlighted a negative payer mix shift, referring to an increase in uninsured patients following losses in health insurance exchange coverage.

For HCA, the change reportedly reduced quarterly pre-tax income by approximately $400 million. The development has raised concerns that other healthcare providers could face higher uncompensated care and additional pressure on margins.

HIMS Stock Reverses After Strong Rally

Hims & Hers shares surged above $35 earlier in the week before giving back roughly half of those gains late in the U.S. session.

Four unapproved peptides received backing from U.S. advisers for pharmacy compounding, potentially opening a significant future market opportunity for Hims & Hers.

Analysts estimate the opportunity could generate approximately $440 million in sales in 2027. However, this is an analyst projection rather than company guidance and therefore remains highly uncertain.

FDA Process Remains Uncertain

The regulatory timeline remains an important consideration.

The advisory vote does not have legal force, and the formal FDA rulemaking process could take up to a year. As a result, investors may need to remain patient before determining whether the potential peptide opportunity can become a meaningful revenue contributor.

Rebound Gains Strength

Hims & Hers Health stock has been under pressure since October, but sentiment shifted in H1 of 2026. After an initial rebound in early March, the stock is gaining further traction, rising around 250% from the $14 bottom and pushing to the $39 level in early July, but failed at moving averages.

HIMS Chart Weekly – The 100 SMA Turned into Support

From a technical perspective, HIMS failed to break above its 50-week moving average and the 100 SMA (green) which have turned into resistance now, signaling and end to the improving short- to medium-term momentum. However, it remains above the 200-week moving average near $38, where the stock seems to be heading.

HIMS Stock Faces a More Cautious Outlook

The sharp selloff may partly reflect broader healthcare sentiment rather than a fundamental change in Hims & Hers’ business.

While large market declines can sometimes create attractive entry points, investors should remain cautious. The potential peptide opportunity is based on analyst estimates, while the regulatory process remains uncertain.

For now, HIMS stock faces a combination of potential long-term growth opportunities and near-term uncertainty, leaving the shares vulnerable to further volatility.

ABOUT THE AUTHOR See More

Skerdian Meta

Lead Analyst

Skerdian Meta Lead Analyst. Skerdian is a professional Forex trader and a market analyst. He has been actively engaged in market analysis for the past 11 years. Before becoming our head analyst, Skerdian served as a trader and market analyst in Saxo Bank's local branch, Aksioner. Skerdian specialized in experimenting with developing models and hands-on trading. Skerdian has a masters degree in finance and investment.

HIMS Stock Jumps 8% as JPMorgan Facility and Analyst Upgrades Fuel Rally

3 weeks ago

Save